Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Enty Tjoa

Enty Tjoa

Atma Jaya Catholic University, Indonesia

Title: Efficacy of Colistin in combination with Carbapenem and Tigecycline in patients with pneumonia caused by multidrug-resistant Acinetobacter baumannii

Biography

Biography: Enty Tjoa

Abstract

Background: Acinetobacter baumannii is a Gram-negative, aerobic and commonly found in hospital environment. It becomes one of the causes of nosocomial infection, including nosocomial pneumonia. Nosocomial infection due to Acinetobacter baumannii has become a global issue due to its multidrug-resistance. Treatment against multidrug-resistant Acinetobacter baumannii (MDRAB) has now become a challenge. At present the following antibiotics: Carbapenem, Colistin, Tigecycline, Sulbactam, Rifampicin, Minocycline, Fosfomycin in the form of combination are taken into account in eradication of MDRAB.

Objective: To assess the efficacy of Colistin in combination with Carbapenem and Colistin with Tigecycline in patients with pneumonia with Acinetobacter baumannii isolated from low respiratory tract.

Methods: This is a retrospective and observational study. The study was conducted in a private hospital in Jakarta, Indonesia, using 4 year period (2011-2015) data extracted from medical records. MDRAB isolated from specimen of low respiratory tract from patients with pneumonia in intensive care unit (ICU) were sorted for this study. Clinical parameters used were as follows: blood leukocyte, differential count, sputum leukocyte, body temperature, procalcitonin, C-reactive protein, lactate, and patient’ survival. The analysis was performed before and after drug administration.

Result: Fifty nine patients with MDRAB were studied. Colistin-Tigecycline combination therapy was used in 11 patients, and Colistin-Carbapenem combination was in 9 patients. Both combination therapies showed efficacy in lowering body temperature after drug administration (p<0.05). Blood leukocyte count also significantly decreased in patients’ with Colistin-Carbapenem regimen (p<0.05). Of other clinical parameters assessed revealed no significant changes.

Conclusion: Colistin-Carbapenem and Colistin-Tigecyline combination therapy can be an option for treating patients with pneumonia caused by multidrug-resistant Acinetobacter baumannii. More studies of antibiotic combination with a bigger sample number are needed to get a high representative data.

Speaker Presentations

Speaker PDFs

Speaker PPTs Click Here